News | January 23, 2024
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Subscribe To Our Newsletter & Stay Updated
